Trials / Terminated
TerminatedNCT00332839
Comparison of CNI-based Regimen Versus CNI-free Regimen in Kidney Transplant Recipients.
Multi-center, Open-label, Prospective, Randomized, Parallel Group Study Investigating a CNI-free Regimen With Enteric-coated Mycophenolate Sodium and Everolimus in Comparison to Standard Therapy With Enteric-coated Mycophenolate Sodium and Ciclosporin Microemulsion in Stable Renal Transplant Patients
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 93 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Calcineurin inhibitors (CNI), a potent immunosuppressive drug used in kidney transplant recipients to prevent graft rejection, may cause renal impairment. The aim of this study is to assess whether a CNI-free regimen with enteric-coated mycophenolate sodium and everolimus is as safe and well tolerated as a standard regimen consisting of enteric-coated mycophenolate sodium and cyclosporine microemulsion without a compromise in therapeutic efficacy while resulting in an improved renal function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Everolimus | Participants, switching from the CsA based treatment, initially received everolimus 1.5 mg/day and then from day 7, 3 mg/day, and then from day 14, the dose was based on the participants' blood level (6-10 ng/ml). Participants, switching from the tacrolimus based treatment, initially received 3 mg/day and then from day 14, the dose was based on the participants' blood level (6-10 ng/ml). |
| DRUG | Cyclosporin A (CsA) | The dose was based on the participants' blood level of C0h (80-150 ng/ml). |
| DRUG | Tacrolimus | The dose was based on the participants' blood level of C0h (5-10 ng/ml). |
| DRUG | Enteric Coated - Mycophenolate Sodium (EC-MPS) | The dose was ≥ 720 mg/day. |
| DRUG | Corticosteroids | Corticosteroids were given according to local standard and/or the Investigators' discretion. |
Timeline
- Start date
- 2005-11-01
- Primary completion
- 2013-03-01
- Completion
- 2013-03-01
- First posted
- 2006-06-02
- Last updated
- 2014-08-28
- Results posted
- 2014-08-28
Locations
11 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT00332839. Inclusion in this directory is not an endorsement.